Antibodies Produced in Response to a Live-Attenuated Dengue Vaccine Are Functional in Activating the Complement System
The Journal of Infectious Diseases · 2023
DOI: 10.1093/infdis/jiac476 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift The Journal of Infectious Diseases, 2023. Verfasst von Eduardo J M Nascimento und 9 weiteren Autor:innen. Beteiligte Einrichtung: Vaccine Research and Analytics, Takeda Vaccines, Inc, Cambridge, Massachusetts, USA. Hauptthemen laut MEDLINE: Dengue, Dengue Vaccines, Dengue Virus. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Takeda Vaccines, Inc.
Abstract (Originalsprache)
Background
Antibody-driven complement system (CS) activation has been associated with protection against symptomatic dengue virus (DENV) infection. Aggregation, opsonization, lysis, and phagocytosis are mechanisms triggered by antibody-antigen immunocomplexes following fixation of the component 1q (C1q) and activation of the classical pathway. As a result, DENV neutralization and clearance are facilitated, whereas antibody-dependent enhancement of infection is inhibited. We investigated the ability of antibodies produced in response to Takeda's dengue vaccine candidate, TAK-003, to fix C1q and activate CS.
Methods
Serum samples were collected from seronegative and seropositive participants in a phase 2 clinical trial (DEN-203), pre- and postvaccination. Samples were evaluated for the presence of complement-fixing antibodies (CFAs) against DENV using a Luminex multiplex-based immunoassay.
Results
TAK-003 elicited production of CFAs against all 4 DENV serotypes, which persisted for 1 year postvaccination, irrespective of baseline serostatus. CFA levels were correlated with neutralizing antibody titers and virus-binding total IgG and IgG1 concentrations. Furthermore, efficiency of CFA fixation was greater in samples with higher polyclonal IgG avidity.
Conclusions
These results indicate that antibodies produced after TAK-003 vaccination are functional in both activating CS and neutralizing virus infection by all DENV serotypes, which may contribute to efficacy of TAK-003. Clinical Trials Registration NCT01511250.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Vaccine Research and Analytics, Takeda Vaccines, Inc, Cambridge, Massachusetts, USA.
- Quantitative Sciences, Takeda Vaccines, Inc, Cambridge, Massachusetts, USA.
- Vaccine Business Unit, Takeda Pharmaceuticals International AG, Zurich, Switzerland.
- VBU Discovery Research, Takeda Vaccines, Inc, Cambridge, Massachusetts, USA.
Förderung
- Takeda Vaccines, Inc
Zitieren
APA
Nascimento, E. J. M., Norwood, B., Kpamegan, E., Parker, A., Fernandes, J., Perez-Guzman, E., Tricou, V., Braun, R., Sharma, M., & Dean, H. J. (2023). Antibodies Produced in Response to a Live-Attenuated Dengue Vaccine Are Functional in Activating the Complement System. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiac476
Vancouver
Nascimento EJM, Norwood B, Kpamegan E, Parker A, Fernandes J, Perez-Guzman E, et al. Antibodies Produced in Response to a Live-Attenuated Dengue Vaccine Are Functional in Activating the Complement System. The Journal of Infectious Diseases. 2023. doi:10.1093/infdis/jiac476
BibTeX
@article{Nascimento2023,
author = {Nascimento, Eduardo J M and Norwood, Brooke and Kpamegan, Eloi and Parker, Allan and Fernandes, Jesuina and Perez-Guzman, Erick and Tricou, Vianney and Braun, Ralph and Sharma, Mayuri and Dean, Hansi J},
title = {Antibodies Produced in Response to a Live-Attenuated Dengue Vaccine Are Functional in Activating the Complement System},
journal = {The Journal of Infectious Diseases},
year = {2023},
doi = {10.1093/infdis/jiac476}
}
EUVIMED